Education
About Us
Working with TipRanks
Follow Us
Context Therapeutics (CNTX)
NASDAQ:CNTX
CNTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.55 - $2.75
Previous CloseN/A
Volume293.07K
Average Volume (3M)193.11K
Market Cap
$84.57M
Enterprise Value-$21.04K
Total Cash (Recent Filing)$35.50M
Total Debt (Recent Filing)$55.08K
Price to Earnings (P/E)―
Beta1.51
Next Earnings
May 07, 2025EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding89,704,190
10 Day Avg. Volume124,659
30 Day Avg. Volume193,109
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio11.60
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$4.50Price Target Upside378.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Context Therapeutics News
PremiumCompany Announcements
Context Therapeutics Begins Phase 1 Trial for CT-95
PremiumCompany Announcements
Context Therapeutics: 2024 Financial and Strategic Highlights
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe potential of the company’s novel T-cell engagers (TCEs) to demonstrate meaningful clinical activity in the ongoing dose-escalation trials, resulting in a significant value inflection for the company.
Financial PerformanceCNTX raised $100M in a private placement, resulting in a year-end cash balance of $94.4M, which is expected to support operations into 2027.
Product DevelopmentContext recently in-licensed two additional TCEs, targeting mesothelin (MSLN) and Nectin-4, holding potential for further value creation with positive initial clinical data.
Bears Say
Clinical DelaysCT-95 first patient dosing slightly delayed to 2Q25 from 1Q25.
Market ConditionsBroad market headwinds continue in 2025 including continued challenging financing conditions and changes to NASDAQ/NYSE listing rules, pressuring small/micro cap biotech stocks.
Valuation ConcernsValuations across much of the biotech space have continued to pullback and reset, for Context too, leading to an increased discount rate in the valuation model.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CNTX FAQ
What was Context Therapeutics’s price range in the past 12 months?
Context Therapeutics lowest stock price was $0.55 and its highest was $2.75 in the past 12 months.
What is Context Therapeutics’s market cap?
Context Therapeutics’s market cap is $84.57M.
When is Context Therapeutics’s upcoming earnings report date?
Context Therapeutics’s upcoming earnings report date is May 07, 2025 which is in 13 days.
How were Context Therapeutics’s earnings last quarter?
Context Therapeutics released its earnings results on Mar 20, 2025. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.092 by $0.062.
Is Context Therapeutics overvalued?
According to Wall Street analysts Context Therapeutics’s price is currently Undervalued.
Does Context Therapeutics pay dividends?
Context Therapeutics does not currently pay dividends.
What is Context Therapeutics’s EPS estimate?
Context Therapeutics’s EPS estimate is -0.06.
How many shares outstanding does Context Therapeutics have?
Context Therapeutics has 89,704,190 shares outstanding.
What happened to Context Therapeutics’s price movement after its last earnings report?
Context Therapeutics reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.092. Following the earnings report the stock price went down -6.098%.
Which hedge fund is a major shareholder of Context Therapeutics?
Currently, no hedge funds are holding shares in CNTX
---
Context Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.50 (378.72% Upside)
$4.50 (378.72% Upside)
Blogger Sentiment
Bullish
CNTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 668.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 6.3%
Last 30 Days ▲ 6.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.73%
12-Months-Change
Fundamentals
Return on Equity
-49.89%
Trailing 12-Months
Asset Growth
510.90%
Trailing 12-Months
Company Description
Context Therapeutics
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
---
CNTX Stock 12 Month Forecast
Average Price Target
$4.50
▲(378.72% Upside)
Technical Analysis
Best Analysts Covering CNTX
1 Year
1 Year Success Rate
4/12 ratings generated profit
1 Year Average Return
-10.10%
reiterated a buy rating last month
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -10.10% per trade.
---